☰

Li Tan, Ph.D - Publications

Affiliations: 
2000-2004 Nanjing University, Nanjing Shi, Jiangsu Sheng, China 
 2004-2009 SIOC,CAS 
 2010-2016 Harvard Medical School, Dana Farber Cancer Institute 
 2016- SIOC,CAS 
Tree Info Similar researchers PubMed Report error

55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Tao Y, Xia W, Zhao Q, Xiang H, Han C, Zhang S, Gu W, Tang W, Li Y, Tan L, Li D, Liu C. Structural mechanism for specific binding of chemical compounds to amyloid fibrils. Nature Chemical Biology. PMID 37400537 DOI: 10.1038/s41589-023-01370-x  0.46
2022 Chan S, Zhang Y, Wang J, Yu Q, Peng X, Zou J, Zhou L, Tan L, Duan Y, Zhou Y, Hur H, Ai J, Wang Z, Ren X, Zhang Z, et al. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. Journal of Medicinal Chemistry. PMID 36358010 DOI: 10.1021/acs.jmedchem.2c01346  0.487
2022 Tan L, Shan H, Han C, Zhang Z, Shen J, Zhang X, Xiang H, Lu K, Qi C, Li Y, Zhuang G, Chen G, Tan L. Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry. PMID 36221183 DOI: 10.1021/acs.jmedchem.2c00408  0.318
2020 Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. PMID 33275901 DOI: 10.1016/j.cell.2020.10.038  0.606
2020 Schröder M, Tan L, Wang J, Liang Y, Gray NS, Knapp S, Chaikuad A. Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. Cell Chemical Biology. PMID 32783966 DOI: 10.1016/J.Chembiol.2020.07.014  0.353
2020 Pinch BJ, Doctor ZM, Nabet B, Browne CM, Seo HS, Mohardt ML, Kozono S, Lian X, Manz TD, Chun Y, Kibe S, Zaidman D, Daitchman D, Yeoh ZC, Vangos NE, ... ... Tan L, et al. Identification of a potent and selective covalent Pin1 inhibitor. Nature Chemical Biology. PMID 32483379 DOI: 10.1038/S41589-020-0550-9  0.362
2020 Zhang YH, Li YF, Wang Y, Tan L, Cao ZQ, Xie C, Xie G, Gong HB, Sun WY, Ouyang SH, Duan WJ, Lu X, Ding K, Kurihara H, Hu D, et al. Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea. Nature Communications. 11: 1473. PMID 32193380 DOI: 10.1038/s41467-020-15324-7  0.353
2019 Tan L, Zhang Z, Gao D, Chan S, Luo J, Tu ZC, Zhang ZM, Ding K, Ren X, Lu X. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. European Journal of Medicinal Chemistry. 166: 318-327. PMID 30731400 DOI: 10.1016/j.ejmech.2019.01.065  0.475
2019 Pinch B, Doctor Z, Browne CM, Seo H, Nabet B, Kozono S, Lian X, Zaidman D, Daitchman D, London N, Gong L, Manz T, Chun Y, Tan L, Marto J, et al. Abstract 2757: Discovery and characterization of covalent Pin1 inhibitors targeted to an active site cysteine Cancer Research. 79: 2757-2757. DOI: 10.1158/1538-7445.Am2019-2757  0.399
2018 Kozono S, Lin YM, Seo HS, Pinch B, Lian X, Qiu C, Herbert MK, Chen CH, Tan L, Gao ZJ, Massefski W, Doctor ZM, Jackson BP, Chen Y, Dhe-Paganon S, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nature Communications. 9: 3069. PMID 30093655 DOI: 10.1038/S41467-018-05402-2  0.322
2018 Weir MC, Shu ST, Patel RK, Hellwig S, Chen L, Tan L, Gray NS, Smithgall TE. Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo. Acs Chemical Biology. PMID 29763550 DOI: 10.1021/Acschembio.8B00154  0.379
2018 Powell CE, Gao Y, Tan L, Donovan KA, Nowak RP, Loehr A, Bahcall M, Fischer ES, Janne PA, George RE, Gray NS. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry. PMID 29660984 DOI: 10.1021/Acs.Jmedchem.7B01655  0.387
2018 Bockorny B, Rusan M, Chen W, Liao RG, Li Y, Piccioni F, Wang J, Tan L, Thorner AR, Li T, Zhang Y, Miao CH, Ovesen T, Shapiro GI, Kwiatkowski DJ, et al. RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade. Molecular Cancer Therapeutics. PMID 29654068 DOI: 10.1158/1535-7163.Mct-17-0464  0.36
2018 Rosas-Diaz T, Zhang D, Fan P, Wang L, Ding X, Jiang Y, Jimenez-Gongora T, Medina-Puche L, Zhao X, Feng Z, Zhang G, Liu X, Bejarano ER, Tan L, Zhang H, et al. A virus-targeted plant receptor-like kinase promotes cell-to-cell spread of RNAi. Proceedings of the National Academy of Sciences of the United States of America. PMID 29363594 DOI: 10.1073/Pnas.1715556115  0.308
2018 Yang G, Wang J, Tan L, Liu X, Munshi M, Chen JG, Xu L, Tsakmaklis N, Demos M, Kofides A, Guerrera ML, Chan GG, Hunter ZR, Patterson C, Castillo JJ, et al. A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88 Blood. 132: 40-40. DOI: 10.1182/Blood-2018-99-119171  0.348
2018 Tan L, Gray NS. When Kinases Meet PROTACs Chinese Journal of Chemistry. 36: 971-977. DOI: 10.1002/Cjoc.201800293  0.303
2017 Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, ... ... Tan L, et al. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology. PMID 29129717 DOI: 10.1016/J.Chembiol.2017.10.005  0.372
2017 Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, ... ... Tan L, et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discovery. PMID 29054992 DOI: 10.1158/2159-8290.Cd-17-0461  0.339
2017 Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. Plos One. 12: e0181178. PMID 28727840 DOI: 10.1371/Journal.Pone.0181178  0.344
2017 Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, et al. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 6. PMID 28561737 DOI: 10.7554/Elife.24523  0.383
2017 Bockorny B, Rusan M, Piccioni F, Tan L, Bass AJ, Hammerman PS. Enhancing targeted therapy of tumors with activating FGFR alterations. Journal of Clinical Oncology. 35: e23134-e23134. DOI: 10.1200/Jco.2017.35.15_Suppl.E23134  0.364
2017 Weir MC, Shu S, Hellwig S, Patel R, Chen L, Tan L, Gray N, Smithgall T. A Unique N-Phenylbenzamide Inhibitor Targeting Non-Receptor Tyrosine Kinases Potently Suppresses AML Cell Growth In Vitro and In Vivo Blood. 130: 3813-3813. DOI: 10.1182/Blood.V130.Suppl_1.3813.3813  0.366
2016 Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, et al. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. PMID 28038940 DOI: 10.1016/J.Bmc.2016.11.034  0.395
2016 Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, et al. Structure-guided development of covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. PMID 28011204 DOI: 10.1016/J.Bmc.2016.11.035  0.39
2016 Tan L, Zhang Z, Gao D, Luo J, Tu ZC, Li Z, Peng L, Ren X, Ding K. 4-Oxo-1, 4-Dihydroquinoline-3-Carboxamide Derivatives as New Axl Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 27379978 DOI: 10.1021/Acs.Jmedchem.6B00608  0.484
2016 Brown W, Tan L, Smith A, Gray NS, Wendt M. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Molecular Cancer Therapeutics. PMID 27371729 DOI: 10.1158/1535-7163.Mct-16-0136  0.325
2016 Li X, Shen J, Tan L, Zhang Z, Gao D, Luo J, Cheng H, Zhou X, Ma J, Ding K, Lu X. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 27155899 DOI: 10.1016/j.bmcl.2016.04.076  0.439
2016 Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, et al. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood. PMID 27151888 DOI: 10.1182/Blood-2016-02-696856  0.357
2016 Ho CM, Donovan-Banfield IZ, Tan L, Zhang T, Gray NS, Strang BL. Inhibition of IKKα by BAY61-3606 Reveals IKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells. Plos One. 11: e0150339. PMID 26930276 DOI: 10.1371/Journal.Pone.0150339  0.338
2016 Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. PMID 26744526 DOI: 10.1158/0008-5472.Can-15-0717  0.333
2015 Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Acs Chemical Biology. PMID 26390252 DOI: 10.1021/Acschembio.5B00655  0.387
2015 Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella KM, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, et al. Development of Selective Covalent JAK3 Inhibitors. Journal of Medicinal Chemistry. PMID 26258521 DOI: 10.1021/Acs.Jmedchem.5B00710  0.38
2015 Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. Plos One. 10: e0128364. PMID 26046350 DOI: 10.1371/Journal.Pone.0128364  0.384
2015 Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discovery. 5: 274-87. PMID 25542448 DOI: 10.1158/2159-8290.Cd-14-0295  0.346
2015 Huang Z, Tan L, Wang H, Liu Y, Blais S, Deng J, Neubert TA, Gray NS, Li X, Mohammadi M. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. Acs Chemical Biology. 10: 299-309. PMID 25317566 DOI: 10.1021/Cb500674S  0.347
2015 Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). Journal of Medicinal Chemistry. 58: 183-96. PMID 25075558 DOI: 10.1021/Jm500480K  0.332
2015 Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 34: 2167-77. PMID 24909170 DOI: 10.1038/Onc.2014.161  0.341
2015 Yang G, Buhrlage S, Tan L, Liu X, Chen J, Hunter Z, Xu L, Tsakmaklis N, Chen J, Patterson CJ, Castillo JJ, Zhang W, Gray N, Treon SP. HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma Blood. 126: 705-705. DOI: 10.1182/Blood.V126.23.705.705  0.331
2015 Yang G, Liu X, Chen J, Xu L, Tsakmaklis N, Chen J, Patterson CJ, Castillo JJ, Cohen P, Tan L, Buhrlage S, Gray N, Treon SP. Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia Blood. 126: 4004-4004. DOI: 10.1182/Blood.V126.23.4004.4004  0.327
2015 Amato K, Wang S, Hastings A, Youngblood V, Santapuram P, Chen H, Cates J, Colvin D, Ye F, Brantley-Sieders D, Cook R, Tan L, Gray N, Chen J. Abstract A12: Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A12  0.359
2015 Gurbani D, Tan L, Ficarro S, Hunter JC, Singer W, Vazquez FB, Xie T, Lim SM, Marto J, Gray NS, Westover KD. Abstract A178: Structure guided development of irreversible inhibitors for TAK1 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A178  0.406
2014 Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 111: E4869-77. PMID 25349422 DOI: 10.1073/Pnas.1403438111  0.38
2014 Wang W, Kong D, Cheng H, Tan L, Zhang Z, Zhuang X, Long H, Zhou Y, Xu Y, Yang X, Ding K. New benzimidazole-2-urea derivates as tubulin inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 4250-3. PMID 25091926 DOI: 10.1016/j.bmcl.2014.07.035  0.441
2014 Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. Journal of Molecular Biology. 426: 2457-70. PMID 24768818 DOI: 10.1016/J.Jmb.2014.04.014  0.381
2014 Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. The Journal of Clinical Investigation. 124: 2037-49. PMID 24713656 DOI: 10.1172/Jci72522  0.34
2014 Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Molecular Cancer Therapeutics. 13: 475-82. PMID 24296828 DOI: 10.1158/1535-7163.Mct-13-0817  0.303
2014 Kim H, Tan L, Weisberg EL, Liu F, Canning P, Choi H, Ezell S, Zhao Z, Wu H, Wang J, Mandinova A, Bullock AN, Liu Q, Lee SW, Gray NS. Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor Acs Chemical Biology. 9: 840-840. DOI: 10.1021/Cb5000949  0.302
2013 Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. Acs Chemical Biology. 8: 2145-50. PMID 23899692 DOI: 10.1021/Cb400430T  0.393
2013 Matthews JM, Tan L, Bhatt S, Patricelli M, Nomanbhoy T, Zhang J, Jiang X, Natkunam Y, Choi HG, Gentles AJ, Martinez E, Zhu D, Chapman JR, Shyam RM, Chinichian S, et al. Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma Blood. 122: 643-643. DOI: 10.1182/Blood.V122.21.643.643  0.37
2012 Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray N, Cohen P, Pedrioli P, Clark K, Alessi DR. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. Plos One. 7: e39132. PMID 22723946 DOI: 10.1371/Journal.Pone.0039132  0.337
2012 Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, Gray N. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. Acs Chemical Biology. 7: 185-96. PMID 21992004 DOI: 10.1021/Cb200305U  0.401
2011 Han S, Pan H, Zhang J, Tan L, Ma D, Yuan J, Wu JR. Identification of a small molecule activator of novel PKCs for promoting glucose-dependent insulin secretion. Cell Research. 21: 588-99. PMID 20877311 DOI: 10.1038/Cr.2010.137  0.444
2009 Chen J, Zhang W, Tan L, Wang Y, He G. Optimization of metabolic pathways for bioconversion of lignocellulose to ethanol through genetic engineering. Biotechnology Advances. 27: 593-8. PMID 19401227 DOI: 10.1016/j.biotechadv.2009.04.021  0.345
2008 Tan L, Ma D. Total synthesis of salinamide A: a potent anti-inflammatory bicyclic depsipeptide. Angewandte Chemie (International Ed. in English). 47: 3614-7. PMID 18383490 DOI: 10.1002/Anie.200800397  0.437
2008 Tan L, Ma D. Synthesis of Salinamide A Synfacts. 2008: 902-902. DOI: 10.1055/S-2008-1077996  0.427
Show low-probability matches.